PARP1 and prostate carcinoma: More recently, therapeutic approaches aimed at broadening the use of PARPi in prostate cancer beyond those harbouring HRR defects include combination strategies that leverage the impact of PARP inhibition on radiosensitisation, immune modulation, and enhanced DNA replication stress, all ultimately leading to enhanced cancer cell lethality (Figure 1).